Journal for ImmunoTherapy of Cancer (Nov 2021)
719 XTX301, a protein-engineered IL-12, exhibits tumor-selective activity in mice without peripheral toxicities and is well tolerated in non-human primates
- Jia Chen,
- Wilson Guzman,
- Parker Johnson,
- Megan McLaughlin,
- Kurt Jenkins,
- Hanumantha Rao Madala,
- Magali Pederzoli-Ribeil,
- Huawei Qiu,
- Ekta Patel,
- Natalia Malkova,
- Sallyann Vu,
- Rebekah O'Donnell,
- Manoussa Fanny,
- Oleg Yerov,
- Caitlin O'Toole,
- Benjamin Nicholson,
- Bill Avery,
- Ronan O'Hagan,
- Jennifer O'Neil
Affiliations
- Jia Chen
- 1 Department of Radiology, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, Zhejiang, China
- Wilson Guzman
- Aff168 grid.467308.e0000 0004 0412 6436EMD Serono Billerica MA USA
- Parker Johnson
- Xilio Therapeutics, Waltham, MA, USA
- Megan McLaughlin
- Xilio Therapeutics, Waltham, MA, USA
- Kurt Jenkins
- Xilio Therapeutics, Waltham, MA, USA
- Hanumantha Rao Madala
- Xilio Therapeutics, Waltham, MA, USA
- Magali Pederzoli-Ribeil
- Xilio Therapeutics, Waltham, MA, USA
- Huawei Qiu
- Xilio Therapeutics, Waltham, MA, USA
- Ekta Patel
- Department of Elderly Medicine, Chelsea and Westminster Hospital, London, UK
- Natalia Malkova
- Xilio Therapeutics, Waltham, MA, United States
- Sallyann Vu
- Xilio Therapeutics, Waltham, MA, United States
- Rebekah O'Donnell
- Xilio Therapeutics, Waltham, MA, United States
- Manoussa Fanny
- Xilio Therapeutics, Waltham, MA, United States
- Oleg Yerov
- Xilio Therapeutics, Waltham, MA, United States
- Caitlin O'Toole
- Xilio Therapeutics, Waltham, MA, United States
- Benjamin Nicholson
- Xilio Therapeutics, Waltham, MA, United States
- Bill Avery
- Xilio Therapeutics, Waltham, MA, United States
- Ronan O'Hagan
- Xilio Therapeutics, Waltham, MA, United States
- Jennifer O'Neil
- Xilio Therapeutics, Waltham, MA, United States
- DOI
- https://doi.org/10.1136/jitc-2021-SITC2021.719
- Journal volume & issue
-
Vol. 9,
no. Suppl 2
Abstract
No abstracts available.
